IL-23: A Potential Drug Target for Cancer and Inflammation (P11049)

Target Name: Interleukin 23 complex (IL-23)

NCBI ID: P11049

Interleukin 23 complex (IL-23)

Other Name(s): IL-23 | IL-23 complex

IL-23: A Potential Drug Target for Cancer and Inflammation

Interleukin 23 complex (IL-23) is a protein that plays a crucial role in the regulation of immune and inflammatory responses. It is a key member of the interleukin family, which includes proteins that regulate various cellular processes in the immune system, including T cell development, activation, and function. IL-23 is a cytokine that is produced by various cell types in response to the presence of an antigen, and it has been shown to play a key role in the regulation of inflammation, tissue repair, and metabolism.

IL-23 has been identified as a potential drug target due to its involvement in a number of diseases, including autoimmune disorders, cancer, and obesity. It is involved in the regulation of T cell development and function, and has been shown to play a role in the development of cancer by promoting the growth and survival of cancer cells. It is also involved in the regulation of inflammation, and has been shown to contribute to the development and progression of a number of inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and asthma.

IL-23 has been shown to promote the growth and survival of various types of cancer cells, including breast, lung, and colon cancer cells. It is also involved in the regulation of cell death, and has been shown to contribute to the development of cancer-associated fibrosis.

In addition to its role in cancer, IL-23 is also involved in the regulation of inflammation and has been shown to contribute to the development and progression of a number of inflammatory diseases. It is a potent regulator of pro-inflammatory cytokines, including TNF-alpha, IL-1, and IL-6, and has been shown to contribute to the development of a number of inflammatory diseases, including rheumatoid arthritis, asthma, and multiple sclerosis.

IL-23 is also involved in the regulation of stem cell proliferation and has been shown to play a role in the development of cancer stem cells. It is a potent regulator of the cell cycle, and has been shown to contribute to the development of cancer stem cells by promoting the growth and survival of stem cells.

In addition to its role in cancer and inflammation, IL-23 is also involved in the regulation of metabolism and has been shown to play a role in the development of obesity. It is a potent regulator of energy metabolism, and has been shown to contribute to the development of obesity by promoting the production of fat.

Overall, IL-23 is a protein that has the potential to be a drug target for a number of diseases, including cancer, autoimmune disorders, and obesity. Further research is needed to fully understand the role of IL-23 in these diseases and to develop effective treatments.

Protein Name: Interleukin 23 Complex (IL-23)

The "Interleukin 23 complex (IL-23) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Interleukin 23 complex (IL-23) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets